pharmaphorum July 15, 2024
Another week, and another study has emerged pointing to a way that GLP-1 receptor agonists may benefit human health.
An observational study carried out by researchers at Oxford University published in The Lancet journal eClinical Medicine has suggested that people who use Novo Nordisk’s Ozempic (semaglutide) for diabetes had a lower risk of cognitive problems, as well as less dependence on nicotine.
The scientists weren’t looking for a benefit – in fact, they were running the trial to investigate a concern that Ozempic may be linked to adverse neuropsychiatric events including suicidal thoughts – so the finding has come as a surprise.
“Our results suggest that semaglutide use could extend beyond managing diabetes, potentially offering unexpected benefits in the treatment...
Today's Sponsors
Today's Sponsor